Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Harvard Bioscience Inc (NASDAQ: HBIO) closed the day trading at $0.69 down -10.10% from the previous closing price of $0.76. In other words, the price has decreased by -$10.10 from its previous closing price. On the day, 1.43 million shares were traded. HBIO stock price reached its highest trading level at $0.76 during the session, while it also had its lowest trading level at $0.6322.
Ratios:
For a better understanding of HBIO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.57. For the most recent quarter (mrq), Quick Ratio is recorded 0.91 and its Current Ratio is at 2.06. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, The Benchmark Company on March 10, 2023, Upgraded its rating to Buy and sets its target price to $4 from $3 previously.
On December 09, 2020, Northland Capital started tracking the stock assigning a Outperform rating and target price of $6.Northland Capital initiated its Outperform rating on December 09, 2020, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’24 when Green James W bought 10,000 shares for $2.91 per share. The transaction valued at 29,100 led to the insider holds 3,111,091 shares of the business.
Green James W bought 20,000 shares of HBIO for $61,400 on Jun 06 ’24. The Chief Executive Officer now owns 3,101,091 shares after completing the transaction at $3.07 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 29877372 and an Enterprise Value of 74580864. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.31 while its Price-to-Book (P/B) ratio in mrq is 0.46. Its current Enterprise Value per Revenue stands at 0.763 whereas that against EBITDA is 25.878.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.35, which has changed by -0.83916086 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $4.70, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is -54.16%, while the 200-Day Moving Average is calculated to be -71.38%.
Shares Statistics:
Over the past 3-months, HBIO traded about 259.94K shares per day on average, while over the past 10 days, HBIO traded about 357720 shares per day. A total of 43.62M shares are outstanding, with a floating share count of 37.64M. Insiders hold about 13.69% of the company’s shares, while institutions hold 70.43% stake in the company. Shares short for HBIO as of 1740700800 were 964351 with a Short Ratio of 3.71, compared to 1738281600 on 758606. Therefore, it implies a Short% of Shares Outstanding of 964351 and a Short% of Float of 2.3800000000000003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
